Background Monoclonal antibodies have gained attention in developing countries owing to
its benefits portrayed by few clinical trials. However, no studies until now have been
undergone in India. Methods A retro-prospective comparative observational study was
conducted in symptomatic COVID19 patients to evaluate the impact of Casirivimab and
Imdevimab antibody cocktail in the high-risk population. Through an extensive data retrieval
for 6 months, 152 samples were documented and sorted into test (Casirivimab and …